| Identification | Back Directory | [Name]
Elgodipine | [CAS]
119413-55-7 | [Synonyms]
Elgodipine
2,6-Dimethyl-4-(2,3-methylenebisoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-isopropyl 5-[2-[methyl(4-fluorobenzyl)amino]ethyl] ester
4-(1,3-Benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3-[2-[[(4-fluorophenyl)methyl]methylamino]ethyl]5-isopropyl ester
3,5-Pyridinedicarboxylic acid, 4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-[2-[[(4-fluorophenyl)methyl]methylamino]ethyl] 5-(1-methylethyl) ester | [Molecular Formula]
C29H33FN2O6 | [MDL Number]
MFCD00865811 | [MOL File]
119413-55-7.mol | [Molecular Weight]
524.58 |
| Hazard Information | Back Directory | [Uses]
Elgodipine (IQB-875 free base) is an orally active dihydropyridine calcium antagonist and an antianginal compound. Elgodipine inhibits both T- and L-type calcium channels (IC50: 32 and 2.3 nM). Elgodipine lowers systemic vascular resistance and improves systolic cardiac function[1][2][3]. | [IC 50]
T-type calcium channel: 32 nM (IC50); L-type calcium channel: 2.3 nM (IC50) | [References]
[1] Kuhn A, et al. Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina. Cardiovasc Drugs Ther. 1995 Aug;9(4):595-600. DOI:10.1007/BF00878092
[2] Lepretre N, et al. Electrophysiological and radioligand binding studies of elgodipine and derivatives in portal vein myocytes. J Pharmacol Exp Ther. 1994 Dec;271(3):1209-15. PMID:7996428
[3] Acharya DU, et al. Anti-ischaemic and haemodynamic effects of elgodipine, a potent new generation calcium antagonist, in chronic stable angina. Eur Heart J. 1994 May;15(5):665-71. DOI:10.1093/oxfordjournals.eurheartj.a060565 |
|
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|